Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects (Q46368521)

21 December 2017

title

Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects (English)

1 reference

21 December 2017

José Manuel Fernández-Real

main subject

interleukins

0 references

author

2

1 reference

21 December 2017

Lina Badimon

5

1 reference

21 December 2017

author name string

G Vázquez-Oliva

1

1 reference

21 December 2017

A Zamora

3

1 reference

21 December 2017

M Vilaseca

4

1 reference

21 December 2017

publication date

1 June 2005

1 reference

21 December 2017

Journal of Human Hypertension

published in

1 reference

21 December 2017

volume

19

1 reference

21 December 2017

issue

6

1 reference

21 December 2017

page(s)

457-462

1 reference

21 December 2017

The pathophysiologic roles of interleukin-6 in human disease

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

AT(1) receptor blockade and atherosclerosis : hopeful insights into vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

Cold pressor test raises serum concentrations of ICAM-1, VCAM-1, and E-selectin in normotensive and hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

7 January 2021

A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

7 January 2021

Blood pressure and inflammation in apparently healthy men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

7 January 2021

Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

7 January 2021

Angiotensin induces inflammatory activation of human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

7 January 2021

Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

7 January 2021

The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001845

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1001845

1 reference

21 December 2017

1 reference

21 December 2017